The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin.

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain and reduce the effects of the ...

Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...